PP-054 EFFICACY OF IDELALISIB IN CLL SUBPOPULATIONS HARBORING DEL(17P) AND OTHER ADVERSE PROGNOSTIC FACTORS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Saved in:
Bibliographic Details
Published inLeukemia research Vol. 38; pp. S44 - S45
Main Authors Sharman, J, Coutre, S, Furman, R, Cheson, B, Pagel, J, Hillmen, P, Barrientos, J, Zelenetz, A, Kipps, T, Flinn, I, Ghia, P, Hallek, M, Coiffier, B, O’Brien, S, Stilgenbauer, S
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 15.10.2014
Subjects
Hematology, Oncology and Palliative Medicine
Online AccessGet full text

Cover

More Information
ISSN:0145-2126
1873-5835
DOI:10.1016/S0145-2126(14)70108-0